BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit

Thursday, June 11, 2026 1 min read

Key Takeaway: BeOne presented significant Phase 3 data regarding BRUKINSA for CLL patients aged 80 and older at EHA 2026. The findings aim to reinforce the benefits of BRUKINSA in this demographic. Further details on the data and its implications were not disclosed in the article.